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Abstract
Introduction
The World Health Organization (WHO) recommends that human papillomavirus (HPV) vac-
cination programs are established to be cost-effective before implementation. WHO recom-
mends HPV vaccination for girls aged 9–13 years to tackle the high burden of cervical
cancer. This review examined the existing evidence on the cost-effectiveness of the 9-valent
HPV vaccine within a global context.
Methods
The literature search covering a period of January 2000 to 31 July 2019 was conducted in
PubMed and Scopus bibliographic databases. A combined checklist (i.e., WHO, Drummond
and CHEERS) was used to examine the quality of eligible studies. A total of 12 studies were
eligible for this review and most of them were conducted in developed countries.
Results
Despite some heterogeneity in approaches to measure cost-effectiveness, ten studies con-
cluded that 9vHPV vaccination was cost-effective and two did not. The addition of adoles-
cent boys into immunisation programs was cost effective when vaccine price and coverage
was comparatively low. When vaccination coverage for females was more than 75%, gen-
der neutral HPV vaccination was less cost-effective than vaccination targeting only girls
aged 9–18 years. Multi cohort immunization approach was found cost-effective in the age
range of 9–14 years. However, the upper age limit at which vaccination was found not cost-
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effective requires further evaluation. This review identified duration of vaccine protection,
time horizon, vaccine price, coverage, healthcare costs, efficacy and discounting rates as
the most dominating parameters in determining cost-effectiveness.
Conclusions
These findings have implications in extending HPV immunization programs whether switch-
ing to the 9-valent vaccine or the inclusion of adolescent boys’ vaccination or extending the
age of vaccination. Further, this review also supports extending vaccination programs to
low-resource settings where vaccine prices are competitive, donor funding is available, bur-
den of cervical cancer is high and screening options are limited.
Introduction
Cervical cancer (CC) is the third most common cancer and the leading cause of cancer-related
deaths in women worldwide [1]. Approximately 570,000 new cases of CC were diagnosed in
2018, composing 6.6% of all cancers in women [1]. The burden of CC is an alarming issue
across the globe, especially in low-and middle-income countries (LMICs). Approximately 85%
of CC cases and 90% of deaths from CC occur in LMICs [1]. Persistent infections with human
papillomavirus (HPV) are a key cause of CC and is an established carcinogen of CC [2]. HPV is
predominantly transmitted to women of reproductive age through sexual contact [3]. Most
HPV infections are transient and can be cleared up within a short period, usually a few months
after their acquisition. However, untreated HPV infections can continue and evolve into can-
cer in some cases. There are more than 100 types of HPV infections, and high-risk types
develop into CC [4]. Thirteen high-risk HPV genotypes are known to be predominantly
responsible for malignant and premalignant lesions of the anogenital area [5], and these are
the leading causes of most aggressive CC [6]. Further, HPV is also responsible for the majority
of anogenital cervical cancers, including anal cancers (88%), vulvar cancers (43%), invasive
vaginal carcinomas (70%), and all penile cancers (50%) globally [4].
The burden of CC (i.e., high incidence and mortality rates) globally is preventable through
the implementation of a primary prevention strategy such as vaccination [1]. There are vac-
cines that can protect common cancer-causing types of HPV and reduce the risk of CC signifi-
cantly. Three types of HPV vaccines, namely bivalent (Cervarix), quadrivalent (Gardasil) and
9-valent vaccine (Gardasil-9), are currently available in the market. Unfortunately, as of March
2017, only 71 countries (37% of all countries) have included HPV vaccines in their national
immunization programs for girls, and 11 countries (6%) included for both sexes [2]. The first
global recommendation on HPV vaccination was proposed by the World Health Organiza-
tion’s Strategic Advisory Group of Experts on Immunization in October 2008 [7], where HPV
vaccination was recommended for girls aged 9–13 years. This recommendation was updated
in April 2014 [8], with the emphasis to include extended 2-dose HPV immunization for girls
aged 9–14 years, who were not immune compromised. With the recent licensing of the
9-valent vaccine and the introduction of various HPV vaccination strategies, an update on the
current recommendations of HPV vaccination are inevitable. The goals of the immunisation
program are to combat the acquisition and spread of HPV infections, and achieving optimum
coverage through effective delivery systems. According to the underlying distribution of HPV
infection types of CC, the 9vHPV vaccine builds population-level strong immunity against
HPV-6, 11, 16, 18, 31, 33, 45, 52, and 58 infections [5] that cumulatively contributed
PLOS ONE Cost-effectiveness evaluations of the 9vHPV vaccine
PLOS ONE | https://doi.org/10.1371/journal.pone.0233499 June 2, 2020 2 / 15
Funding: The author(s) received no specific
funding for this work.
Competing interests: The authors have declared
that no competing interests exist.
approximately 89% of all CCs globally [9]. With respect to the primary prevention of HPV
infection, it is expected that the 9vHPV vaccine can reduce the lifetime risk of diagnosis with
CC by an additional 10% in immunised cohorts compared with the 4vHPV vaccine and by an
additional 52% in non-vaccinated cohorts [10].
This review aims to update the current evidence on the economic viability of HPV vaccina-
tion. In addition, this study aims to examine the cost-effectiveness of the 9-valent vaccine
when boys are included and when age cohorts are varied, from the global context. This review
may be used as comprehensive evidence of general trends on the ongoing cost-effectiveness
evaluation of HPV vaccine.
Materials and methods
Study design
Published original academic literature that examined the cost-effectiveness of 9vHPV vaccina-
tion were included in this systematic review. A wide type of study perspectives including socie-
tal and health systems perspectives were employed. A search strategy was adopted considering
all countries regardless of perspective or vaccine delivery strategy. A combined WHO [11],
Drummond [12] and CHEERS [13] checklist was used to evaluate the quality of included
studies.
Search strategy and sources
A literature search for the period of January 2000 to 31 July 2019 was conducted using PubMed
and Scopus bibliographic databases. This study searched for articles with no language restric-
tions. The literature search was performed by searching Scopus and PubMed databases to
identify relevant articles following the inclusion criteria. Search inclusion terms included ‘eco-
nomic evaluation’, ‘cost-effectiveness’, ‘analysis’, ‘human papillomavirus’, ‘HPV’, ‘vaccine’,
‘vaccinated’, ‘vaccination’, ‘cervical cancer’, ‘non-valent’, ‘9 or nine-valent’ (Appendix A). Ref-
erence lists for selected studies were checked to identify relevant studies for inclusion.
Study selection
Three authors (RAM, SAK and GMO) of the review team independently examined the titles
and abstracts of the articles that met the selection criteria. The existing academic literature in
the cost-effectiveness of 9vHPV vaccination was searched. Language restrictions were not
applied. The eligibility of studies for inclusion was determined following a three-stage screen-
ing process. The first stage involved screening studies by title to eliminate duplicates. The sec-
ond stage required the reading of abstracts to determine their relevance to this study. The
third stage necessitated the reading of full texts of the retained studies as reflected in Fig 1.
RAM carried out and recorded the above process, and shared the record with SAK and GMO
for verification. Discrepancies were discussed and resolved by consensus.
Data checking
The study strategy followed a number of checks to ensure consistency of approach, including a
discussion about discrepancies within the study team. For each outcome and model input
parameters, the authors identified the proportion of missing observations. Datasets were com-
bined to form a new master dataset where model input assumptions and outcome-related
parameters used in the original studies were included. Further, three authors independently
assessed the analytical quality of the preliminary selected studies using appropriate tools for
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examining risk of bias. Disagreements on inclusions were resolved by discussion with a third
review author.
Data extraction (selection and coding)
The study selection process was conducted following the PRISMA guidelines [14]. Data were
extracted to develop a comprehensive data matrix which summarises the study characteristics
such as authors, settings, perspective, threshold, outcome-related parameters and other neces-
sary information.
Strategy for data synthesis
Three authors (RAM, SAK and GMO) independently reviewed the titles and abstract. Data
from all eligible studies were extracted by the same two authors using a standardized data col-
lection form. A matrix was developed to summarise the characteristics and findings of the
studies. Studies were characterized by incorporating four themes: (i) study used 9vHPV vac-
cine to examine the cost-effectiveness, (ii) target population demographic characteristics (e.g.,
gender-neutral and multiple age cohort immunisation), (iii) study perspectives, model and
economic level of each country, and (iv) model input and outcome-related parameters.
To compare findings across the selected studies, incremental cost-effectiveness ratios
(ICERs) and standardized cost-effectiveness were outlined. In terms of standardized cost-effec-
tiveness scenarios, these studies used the heuristic cost-effectiveness threshold guided by the
WHO [15], wherein an intervention or program was evaluated to be cost-effective if the ICER/
DALYs averted was less than three times a country’s annual per capita Gross Domestic Product
(GDP). Further, the WHO constructed three broad decision rules: (i) an intervention or pro-
gram was recommended as very cost-effective if ICER/DALYs averted <1 time GDP threshold;
(ii) cost-effective if ICER/DALYs averted� 1 time GDP threshold and� 3 times GDP thresh-
old; and (iii) not cost-effective if ICER/DALYs averted >3 times GDP threshold [16]. Examin-
ing whether an ICER offered by any strategy signifies value for money requires comparison to
a cost-effectiveness threshold (CET). The CET refers to the health effects foregone (i.e., oppor-
tunity costs) related to resources being devoted to an intervention and consequentially being
Fig 1. PRISMA flow-chart for systematic review of studies.
https://doi.org/10.1371/journal.pone.0233499.g001
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unavailable for other health-care priorities. Policy makers should be willing to invest their lim-
ited resources in the strategy offering the greatest health gains. The review may serve as an
important evidence with respect to methodological and current practices of cost-effectiveness
evaluation studies such as determination of study research questions; the study perspective
adopted, the duration of vaccine protection, time horizon and discount rate; explanation of
model performed for data analysis; model input assumptions behind the estimation of associ-
ated costs and outcome parameters; reporting of ICERs; most dominant parameters of sensi-
tivity analysis; examination of study conclusions and recommendations as well as financial
disclosure of the selected studies.
Study characteristics
Four hundred and eighty-one articles were yielded through the primary search, of which 78
articles were discarded because of duplication. Fifty-one articles were considered for full-text
review after screening by title and abstract. Of these, 12 articles were eligible for the final
review (Table 1). Three hundred fifty-two articles were excluded from this study following the
inclusion criteria. The reasons for exclusion were: conference abstract (n = 58), reviews or edi-
torials or commentary (n = 160), not cost-effectiveness evaluations (n = 60), did not use
9-valent vaccine (4v-HPV, 2v-HPV; n = 72) and insufficient information (n = 2). Finally, 12
articles were included in this review (Fig 1).
Settings and funding
Single country studies mostly focused on high-income settings [4,17,26–28,18–25] (Table 2).
However, a single study was found that covered two low-income countries (e.g., Kenya and
Uganda) [29]. Eight studies were funded by research organisations [4,17,19,21–24,29], while
two studies did not state funding sources [20,27]. The Bill and Melinda Gates Foundation was
the sole funder of one study [29] and three studies were funded by the Centre for Disease Con-
trol (CDC) [21,24,27]. Further, five studies were conducted in United States [20,22,24,27,28],
one study was conducted in each of Germany [23], Italy [4], China [18], Australia [25], Austria
[17], and Canada [19]. Low resource countries mostly depend on external funding agency for
HPV vaccine programs, hence these countries may have less impetus for cost-effectiveness
studies to inform local decision making as priorities are driven by external considerations.
Study questions
Most studies (8 out of 12 studies) investigated the cost-effectiveness of introducing 9vHPV vac-
cination to preadolescent girls aged 12 or younger [4,17–19,22,24–26,29]. Four studies assessed
vaccinating 12 years or older girls [20,23,27,28]. All studies investigated vaccination either as
an addition to existing screening programs or (more commonly) as opportunistic preventive
programs or none at all. Further, most studies considered a range of vaccination and screening
options to find the most cost-effective combination.
Analytical model
Nine studies used a dynamic economic model for examining the cost-effectiveness of HPV
vaccination programs [4,17,27,28,18,20–26], two studies used a static model [19,29], and
one study used a Markov model for analytical exploration [18] (Table 2). However, some
studies did not explicitly account for the pathologic transition from HPV-acquisition to
HPV-associated disease [4,18,25,27,28], pathologic transition [4,23] and herd immunity
[17,19,20,24,27,28].
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Thresholds and perspectives
In terms of the cost-effectiveness scenario, four studies used the heuristic cost-effectiveness
threshold proposed by the WHO. These studies used either one or three times GDP per cap-
ita [18,19,24,29]. The majority of studies adopted local thresholds (e.g., willingness to pay)
while three studies considered both thresholds of GDP per capita and willingness to pay
[18,24,29]. Apart from these studies, seven studies undertook an evaluation from a societal
perspective [19,22–24,27–29], and four studies utilised the health system perspective
[4,18,20,25]. Several studies used the societal perspective and included all vaccination costs,
relevant direct medical costs, and gains in quality and length of life without considering who
incurred the costs or who received the benefits (Table 2). However, these selected studies
reported little about the indirect costs and productivity losses which are significant from the
societal perspective.
Table 1. Characteristics of twelve included cost-effectiveness studies of 9vHPV vaccination.
Characteristics Number of studies (n) Percentage (%)
Selected articles 12 100
Year of publication
2014 2 17
2016 7 58
2017 2 17
2018 1 8
Name of Journal
BMC Infectious Diseases 2 17
Cost Effectiveness and Resource Allocation 1 8
Expert Review of Pharmacoeconomics & Outcomes Research 1 8
Human Vaccines & Immunotherapeutics 1 8
International Journal of Cancer 1 8
The Lancet Public Health 1 8
PLoS ONE 1 8
The Journal of Infectious Diseases 2 17
Vaccine 1 8
Journal of the National Cancer Institute 1 8
Study setting
Australia 1 8
Austria 1 8
Canada 1 8
China 1 8
Germany 1 8
Italy 1 8
Kenya and Uganda 1 8
United States 5 42
Main location of first author
Research institute 8 67
Research group 1 8
Hospital or University 3 25
Conflict of interest
Yes 6 50
No 6 50
https://doi.org/10.1371/journal.pone.0233499.t001
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Vaccine coverage
The assumptions on vaccine coverage are significant in influencing the potential impact of
HPV vaccine on HPV related diseases. Four selected studies assumed a vaccination coverage
rate of 90% or above [18,22,23,29]. The vaccine coverage might be varied in terms of study set-
tings as well as from a gender point of view. Among the selected studies, three studies consid-
ered vaccine coverage rates of 26–60% for females and 25–40% for males [17,27,28], and three
studies considered a 46–80% vaccine coverage rate [19,20,25]. Three studies grouped vaccina-
tion coverage rate by gender, assumed 25–60% for females and 11–40% for males [24,27,28].
The remaining studies did not specify the vaccination coverage rate [24].
Vaccine efficacy
Most studies considered a vaccine efficacy rate ranged from 95–100% against HPV infections
except the study of Simms et al. (2016) [25], which considered a vaccine efficacy rate of only
59%. The study conducted in two East African countries (Kenya and Uganda) used a 100%
vaccine efficacy rate in case of 9vHPV [29]. Most studies (n = 10/12) used a 95% vaccine effi-
cacy rate [4,17,27,28,18–24,26].
Number of vaccine dose and delivery route
Eight studies used a three-dose schedule of 9vHPV vaccine. Most studies were conducted in
developed countries [18–21,24,27–29] and the other two studies were conducted in low- and
middle-income countries (LMICs) [18,29]. Further, one study conducted in the United States
[21] used both 2- and 3-dose vaccines. Diverse vaccine delivery routes were evidenced across
the selected studies. Nine studies used the vaccine delivery route of a national immunisation
program for the target population [4,18–21,25,27–29]. Two studies conducted in Austria [17]
and United States [24], used a universal immunisation strategy to deliver the vaccine. Only
one cost-effectiveness exploration of 9vHPV vaccine was conducted in Germany [23] and it
used a vaccine delivery route through social health insurance.
Duration of vaccine protection, herd immunity effect, and discounting rate
Most studies (11/12) assumed lifelong vaccine protection while only one study assumed a
shorter duration of protection of 20 years [19]. Half of the studies specified herd immunity
due to vaccination [17,19,20,24,27,28]. The remaining six studies did not consider the indirect
effect of vaccination. Regarding the discount rate, majority of the studies (11/12) used 3% dis-
count rate, while one study considered a 5% discount rate to adjust for future values in terms
of economic value and health outcome [25].
Quality of included studies
The quality scores were assigned using the Consensus Health Economic Criteria (CHEC) list, a
checklist that can be used to critically evaluate published economic evaluations [30]. Table 3
showed the extent to which the reviewed studies followed the standards of reporting economic
evaluations based on the WHO guidance [11], Drummond [12] and the Consolidated Health Eco-
nomic Evaluation Reporting Standards (CHEERS) [13]. All studies clearly identified the study
question, intervention(s), comparator(s) perspectives, time horizon and discounting rates. Most
studies performed sensitivity analyses (11/12; 92%) to assess the robustness of concerned study
findings. Most studies clearly described the measurements and the assumptions for measuring the
costs (11/12, 92%). The choice of model used was justified in all studies, where dynamic transmis-
sion model was adopted to capture herd immunity. The currency and price data were also
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reported in all studies. 10 (83%) out 12 studies disclosed the funding sources. However, only 8
studies (67%) reported the measurement of effectiveness from synthesis-based estimates, either
through the combination of several randomized trials or the use of systematic reviews.
Results
Ten studies concluded that their evaluation of 9vHPV vaccination was found to be cost-effec-
tive (Table 4) while the remaining two studies did not find cost-effectiveness [27,28]. Further,
five studies exhibited a ‘very cost-effective’ decision [4,18,19,23,29] and four studies found
‘cost-savings’ [17,22,24,27]. In the context of high-income countries (e.g., Canada and Aus-
tria), introduction of 9vHPV vaccination was a cost-effective decision to prevent cervical can-
cer in adolescent girls, as the incremental cost of vaccine was less than US$23-US$47.
However, in low and middle-income countries (e.g., Kenya and Uganda), the ICER of 9vHPV
vaccine must not be priced over US$8.40-US$9.80 [19,29]. Two US based studies concluded
that the cost-effectiveness exploration of 9vHPV vaccine was more likely to be ‘cost-saving’
regardless of cross-protection assumption [24,27]. Most studies used ‘quality-adjusted life
year’ (QALYs) as the unit of measurement. In addition, selected studies explored the cost-effec-
tiveness decision using WTP thresholds that depend on country settings. Cost-effectiveness
decision differs with country specific vaccine prices. For example, two studies conducted in
the US, considered two different vaccine prices per dose, US$162.74 and US$174, respectively.
However, both studies confirmed that the introduction of 9vHPV vaccine was not cost-effec-
tive. Four studies reported cost-effectiveness of 9vHPV vaccine for gender-neutral approaches
[17,20,24,27] and three studies found it a ‘cost-effective’ or ‘cost-saving’ decision [17,24,27].
The remaining eight studies suggested vaccinating girls only. In terms of key drivers of cost-
effectiveness, this review identified duration of vaccine protection [17,19,25], time horizon
[28], vaccine price [4,19,20,23–25,27,28], healthcare costs [22], vaccine efficacy [19,22], vaccine
coverage [19,22] and discounting rates [17,19,23,29] as the most influential parameters.
Discussion
The HPV vaccination is one of the cornerstones of CC prevention worldwide. This study
explored the cost-effectiveness of 9vHPV vaccination by reviewing 12 cost-effectiveness
Table 3. Extent to which included studies met standard reporting recommendations.
Explained recommendations Number of studies fulfilling Percentage (%)
Research question or objective clearly stated 10/12 83
Described intervention and comparator 10/12 83
Exploration of effectiveness reported 11/12 92
Single study-based estimates 8/12 67
Synthesis-based estimates 10/12 83
Assumption of costs and outcomes specified 11/12 92
Currency and price data reported 12 100
Choice of model justified 12 100
Perspective specified 12 100
Time horizon specified 12 100
Discounting rates specified 12 100
Calculated and reported ICER or cost-saving 12 100
Sensitivity analysis performed 11/12 92
Conclusions follow from the data reported 12 100
Disclosed funding source(s) 10/12 83
https://doi.org/10.1371/journal.pone.0233499.t003
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evaluations in order to inform and expand knowledge on the cost-effectiveness of 9vHPV vac-
cines. Most studies were conducted from a developed country perspective and two studies
were performed from a LMIC perspective. However, a higher incidence of cervical cancer in
LMICs is a serious public health concern, which warrants more evidence for effective decision
Table 4. Summary of the results of the selected studies.
Author Vaccine
efficacy
Vaccine
coverage
Duration of
vaccine
protection
Herd
effect
Vaccine
price per
dose
Unit of cost-
effectiveness
GDP per
capita
Incremental cost-
effectiveness
ration (ICER)
Conclusion or
recommendation
Study funder
Kiatpongsan
et al. [29]
100% 100% Lifetime No US$
90.25
QALYs Kenya =
$1,349.97,
Uganda = $
674.05
Very cost-
effective if
additional cost of
9vHPV vaccine
per course� $9.8
in Kenya &� 8.4
in Uganda
Very cost-effective
for both countries
(Kenya & Uganda)
The Bill and Melinda
Gates Foundation
Laprise et al.
[22]
95% 90% Lifetime No US$ 158 QALYs Cost saving to US
$ 500
Cost saving CDC
Largeron
et al. [23]
96% 90% Lifetime No € 140 QALYs £30,000 € 329 / QALY Highly cost-effective Sanofi Pasteur MSD
(SPMSD).
Mennini
et al. [4]
96% 90% lifelong No € 80.00 QALYs € 40,000 € 10,463 / QALY Highly cost-effective Sanofi Pasteur MSD
Mo et al. [18] 96.7% 20% lifetime No USD
149.03
QALYs USD
23,880
US$ 5,768 /
QALY
Highly cost-effective
with screening 1
+ 9vHPV,—Cost-
effective with
screening 2 + 9vHPV
The Japan Society
for the Promotion of
Sciences, the
National Centre for
Child Health and
Development, and
the Chinese Natural
Sciences Foundation
Simms et al.
[25]
59% 70% lifelong No ns QALYs AUD
30,000
Cost-
effectiveness if
the additional
cost per dose is
US$18–28
Cost-effective National Health and
Medical Research
Council, Australia
Boiron et al.
[17]
98% Female:
60%
Male:
40%
Lifelong Yes US$
147.15
QALYs US$
44,767.35
Cost-saving at
vaccine price up
to US$ 166.77
Cost-saving Sanofi Pasteur MSD
Brisson et al.
[24]
95.0% Not
stated
Lifelong Yes US$ 158 QALYs US$
48,373.88
Cost-saving
regardless of
cross-protection
assumptions
Cost-saving if
additional cost of
vaccine per
dose < US$ 13
CDC, Canadian
Research Chair
Program
Chesson
et al. [27]
95.0% Female:
25.8%
Male:
11.7%
Lifelong Yes US$
162.74
QALYs US$
52,787.03
Cost-saving
regardless of
cross-protection
assumptions
(<$0)
Cost-saving Not stated
Chesson
et al. [28]
95.0% Female:
46%
Male:
25%
Lifelong Yes US$
162.74
QALYs US$
52,787.03
US$ 111,446 /
QALY
Not cost-effective CDC, Canada
Research Chair
Program, Canadian
Institute for Health
Research
Chesson
et al. [20]
95.0% 46% Lifelong Yes US$ 174 QALYs US$
52,787.03
US$ 228,800 /
QALY
Not cost-effective Not stated
Drolet et al.
[19]
95.0% 80% 20years Yes US$
90.25
QALYs US$
50,440.44
US$ 11,593
/QALY
Very cost-effective if
additional cost of
vaccine per
dose� US$ 22.80
Canadian Research
Chair Program
https://doi.org/10.1371/journal.pone.0233499.t004
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making [31]. The economic viability of gender-neutral 9vHPV vaccination was confirmed by
three studies [17,24,27]. Cost-effectiveness exploration depends on the coverage of vaccination
from the perspective of gender. For example, if the vaccine coverage for female recipients is
80% or above, the majority of the anogenital CC including vulvar cancers, invasive vaginal car-
cinomas cancers in females could be prevented. As a result, introduction of 9vHPV vaccination
for boys is relatively less important compared with girls as high economic costs are involved
without additional benefits gained, both from the societal and health system perspectives.
Therefore, achieving optimal coverage of vaccination in females should remain a priority. This
is of primary significance for LMICs settings since it is more effective and economically viable
to prevent CC in females. However, it is also important to note that past studies paid little
attention to the broader benefits of vaccination among male cohorts to prevent penile, anal,
and oropharyngeal cancers. Exclusion of these diseases related to males may undermine the
effectiveness of reducing CC. Gender-neutral vaccination might have several benefits includ-
ing herd protection for boys. Moreover, it may provide indirect protection to unvaccinated
women and direct protection to homosexual men. Therefore, this vaccination strategy should
be further considered in country-level immunization programs by underlining other parame-
ters including disease burden, sexual behaviour in a country (e.g., homosexual intercourse),
equity, budget impact, and affordability.
Despite different methodologies and various assumptions, most studies were consistent in
their conclusion that multiple age cohort vaccination was economically viable. Nevertheless,
there was an upper age limit at which HPV vaccination was no longer cost-effective, and
should be interpreted cautiously as several studies evaluated the cost-effectiveness in a single
age range only and did not compare to the next age range in a progressive manner. Subse-
quently, this could result in an overestimation of the cut-off age range for vaccination. The
protection duration from vaccination has a large impact on the cost-effectiveness of multi-
cohort vaccination, with most studies assuming life-long protection. Therefore, the use of
ICERs based on the conventional evaluation of 10-year protection may be more representative
of real-life effectiveness rather than the use of ICER based on lifetime protection. The cost-
effectiveness of HPV vaccination is also dependent upon the levels of vaccine coverage, com-
pliance, and vaccine price.
Most studies presumed a high rate of vaccination coverage, e.g., assumed that 70% of the
target population will receive full doses of vaccination. However, not everyone completed full
doses (i.e., two or three doses) within the recommended time frame. Therefore, cost-effective-
ness evaluation may underestimate or overestimate the actual costs and benefits. The analytical
model outcomes in terms of herd immunity is only hypothetical unless the coverage level
increases among the study cohort. Further, it is also indeterminate how non-compliance may
consequently influence vaccine efficacy, effectiveness and duration of protection. Model input
assumptions regarding the 9vHPV vaccine price also influence the observed cost-effectiveness
outcomes. Prices for 9vHPV vaccine are currently not specified, particularly, in lower-income
countries. Hence, the cost-effectiveness of 9vHPV vaccine is still indeterminate and there is no
exclusive evidence of greater cost-effectiveness than the older licensed HPV vaccines.
Therefore, once the 9-valent vaccine price is fixed, including support by the GAVI vaccine-
alliance, reassessment of cost-effectiveness of 9vHPV vaccine is necessary. Another model
input assumption that may influence the cost-effectiveness is the inclusion or exclusion of
herd immunity effects based on the type of model acceptance. Two studies [19,29] constituted
the static model as an analytical exploration which did not confirm herd immunity effects.
Generally, the cost-effectiveness evaluations of HPV vaccine should use a dynamic model for
exploration because economic evaluations for primary prevention strategy should be deter-
mined by societal benefits (e.g., indirect impacts on population not immunised) rather than
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individual demands [32]. However, the application of a static model in these two studies may
underestimate or overestimate the benefits of vaccination. If an HPV vaccination program is
exhibited to be cost-effective considering a static model for analytical exploration, it is antici-
pated to be even very cost-effective when a dynamic model is considered [32].
There are several types of cost-effectiveness threshold. The majority of the studies used the
cost-effectiveness demand side-threshold (e.g. willingness-to-pay). In health-related explora-
tions, a willingness-to-pay threshold signifies an evaluation of what a consumer of health care
might be prepared to pay for the health benefit–given other competing demands on that con-
sumer’s resources. There are also supply-side thresholds that resource allocation mechanism
takes into account. For example, estimates of health status are predetermined since when an
insurance company or other provider spends some of its available budget on a new interven-
tion it is therefore required to decrease its funding of previous interventions. In considering
the choice of the type of cost-effectiveness threshold to use, the concept of opportunity cost
may be the one most relevant to providers who are primarily concerned with using available
resources to maximise improvements in health status. In response to the implementation of a
new intervention, decision-makers need estimates of both the health that might be gained else-
where through the alternative use of the resources needed for the new intervention and the
health that is likely to be lost if the new intervention is not used.
This review has some limitations. The cost-effectiveness evaluation based on GDP based
thresholds of 1–3 times of GDP per capita might be misleading for country-level decision mak-
ing due to a lack of country specific thresholds [33]. It is uncertain whether this threshold truly
reflects the country’s affordability or societal willingness to pay for additional health gains.
Additionally, GDP is originally intended to measure the experience of people residing in urban
areas and thus it may not actually reflect the experience of the entire population in a country,
especially those living in rural areas. Apart from an economic standpoint, other factors should
be considered for the national immunization program, such as budget availability, political
issues, cultural influences and availability of healthcare workforce.
Conclusions
There are a limited number of studies that showed conclusive evidence of cost-effectiveness of
the 9vHPV vaccine. The inclusion of adolescent males in HPV vaccination programs is cost-
effective subject to vaccine price or coverage of females being low and HPV-associated male
diseases are taken into account. Multiple age cohort vaccination strategy is likely to be cost-
effective in the age range of 9–14 years, but the upper age limit at which HPV vaccination is no
longer cost-effective requires further investigation. Vaccine coverage, price, duration of pro-
tection and discount rates are important parameters for considering the uptake of HPV vacci-
nation. Nonetheless, the present study findings may serve as useful evidence for health policy-
makers and healthcare providers in taking decision about HPV national immunization pro-
grams using the new 9vHPV vaccine or inclusion of adolescent boys’ for vaccination or
extending the age of immunization.
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